Tectonic Therapeutic (TECX) Competitors $26.18 +0.78 (+3.07%) Closing price 04:00 PM EasternExtended Trading$26.15 -0.03 (-0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TECX vs. DYN, IMCR, SPRY, TVTX, CDTX, AUPH, JANX, AMPH, EWTX, and SDGRShould you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include Dyne Therapeutics (DYN), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Travere Therapeutics (TVTX), Cidara Therapeutics (CDTX), Aurinia Pharmaceuticals (AUPH), Janux Therapeutics (JANX), Amphastar Pharmaceuticals (AMPH), Edgewise Therapeutics (EWTX), and Schrodinger (SDGR). These companies are all part of the "pharmaceutical products" industry. Tectonic Therapeutic vs. Its Competitors Dyne Therapeutics Immunocore ARS Pharmaceuticals Travere Therapeutics Cidara Therapeutics Aurinia Pharmaceuticals Janux Therapeutics Amphastar Pharmaceuticals Edgewise Therapeutics Schrodinger Dyne Therapeutics (NASDAQ:DYN) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk. Which has more volatility & risk, DYN or TECX? Dyne Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.27, meaning that its stock price is 227% more volatile than the S&P 500. Which has better earnings & valuation, DYN or TECX? Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$317.42M-$3.86-3.26Tectonic TherapeuticN/AN/A-$57.98M-$4.04-6.48 Does the media refer more to DYN or TECX? In the previous week, Dyne Therapeutics had 4 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 6 mentions for Dyne Therapeutics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.69 beat Dyne Therapeutics' score of 0.67 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders & institutionals have more ownership in DYN or TECX? 96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 14.1% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 38.0% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is DYN or TECX more profitable? Tectonic Therapeutic's return on equity of -30.13% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -64.12% -56.75% Tectonic Therapeutic N/A -30.13%-28.33% Do analysts prefer DYN or TECX? Dyne Therapeutics currently has a consensus price target of $33.80, indicating a potential upside of 168.68%. Tectonic Therapeutic has a consensus price target of $80.33, indicating a potential upside of 206.85%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Dyne Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.00Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryTectonic Therapeutic beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks. Get Tectonic Therapeutic News Delivered to You Automatically Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECX vs. The Competition Export to ExcelMetricTectonic TherapeuticMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$489.83M$3.09B$5.83B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-6.4821.1631.1625.99Price / SalesN/A396.94474.86122.97Price / CashN/A43.0937.1558.38Price / Book1.738.069.116.38Net Income-$57.98M-$54.72M$3.26B$265.56M7 Day Performance11.36%2.52%2.06%1.89%1 Month Performance17.82%7.54%5.08%1.23%1 Year Performance52.21%13.01%31.26%21.10% Tectonic Therapeutic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECXTectonic Therapeutic2.73 of 5 stars$26.18+3.1%$80.33+206.9%+56.3%$489.83MN/A-6.48120Positive NewsDYNDyne Therapeutics3.2983 of 5 stars$11.54+2.6%$34.94+202.8%-74.0%$1.64BN/A-2.99100IMCRImmunocore1.851 of 5 stars$32.15+0.8%$58.00+80.4%-10.6%$1.61B$310.20M-80.34320Positive NewsSPRYARS Pharmaceuticals2.7275 of 5 stars$16.24-0.8%$31.00+90.9%+11.0%$1.59B$89.15M-101.3190Insider TradeTVTXTravere Therapeutics2.4499 of 5 stars$17.58+1.7%$32.21+83.2%+104.7%$1.57B$233.18M-8.61460CDTXCidara Therapeutics3.607 of 5 stars$62.08+0.1%$64.14+3.3%+419.2%$1.56B$1.27M-5.5390AUPHAurinia Pharmaceuticals2.7024 of 5 stars$11.40-0.3%$12.00+5.3%+83.3%$1.50B$235.13M26.58300Positive NewsJANXJanux Therapeutics2.1306 of 5 stars$23.95+5.6%$91.89+283.7%-46.5%$1.43B$10.59M-13.2630AMPHAmphastar Pharmaceuticals3.2976 of 5 stars$30.53+11.6%$31.50+3.2%-36.7%$1.41B$731.97M11.392,028EWTXEdgewise Therapeutics2.3662 of 5 stars$13.52+4.0%$41.60+207.8%-30.2%$1.41BN/A-8.6660Analyst ForecastSDGRSchrodinger3.0987 of 5 stars$18.77+0.8%$32.75+74.5%-2.5%$1.38B$207.54M-7.57790 Related Companies and Tools Related Companies Dyne Therapeutics Competitors Immunocore Competitors ARS Pharmaceuticals Competitors Travere Therapeutics Competitors Cidara Therapeutics Competitors Aurinia Pharmaceuticals Competitors Janux Therapeutics Competitors Amphastar Pharmaceuticals Competitors Edgewise Therapeutics Competitors Schrodinger Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TECX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.